Chimeric Antigen Receptor T Cell Therapy in Hematology

被引：9

作者：

Ataca, Pinar ^{[1
]}

Arslan, Onder ^{[1
]}

机构：

[1] Ankara Univ, Fac Med, Dept Hematol, TR-06100 Ankara, Turkey

来源：

TURKISH JOURNAL OF HEMATOLOGY | 2015年 / 32卷 / 04期

关键词：

Chimeric antigen receptor T cell; Hematological malignancies; ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANTITUMOR-ACTIVITY; CANCER REGRESSION; GENE-THERAPY; IN-VIVO; LYMPHOCYTES; TRANSDUCTION; LYMPHOMA;

D O I：

10.4274/tjh.2015.0049

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

It is well demonstrated that the immune system can control and eliminate cancer cells. Immune-mediated elimination of tumor cells has been discovered and is the basis of both cancer vaccines and cellular therapies including hematopoietic stem cell transplantation. Adoptive T cell transfer has been improved to be more specific and potent and to cause less off-target toxicity. Currently, there are two forms of engineered T cells being tested in clinical trials: T cell receptor (TCR) and chimeric antigen receptor (CAR) modified T cells. On 1 July 2014, the United States Food and Drug Administration granted 'breakthrough therapy' designation to anti-CD19 CAR T cell therapy. Many studies were conducted to evaluate the benefits of this exciting and potent new treatment modality. This review summarizes the history of adoptive immunotherapy, adoptive immunotherapy using CARS, the CAR manufacturing process, preclinical and clinical studies, and the effectiveness and drawbacks of this strategy.

引用

页码：285 / 294

页数：10

共 65 条

[1]

[Anonymous], 1909, Ned. Tijdschr. Geneeskd.

[2] CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia [J].

Brentjens, Renier J. ;

Davila, Marco L. ;

Riviere, Isabelle ;

Park, Jae ;

Wang, Xiuyan ;

Cowell, Lindsay G. ;

Bartido, Shirley ;

Stefanski, Jolanta ;

Taylor, Clare ;

Olszewska, Malgorzata ;

Borquez-Ojeda, Oriana ;

Qu, Jinrong ;

Wasielewska, Teresa ;

He, Qing ;

Bernal, Yvette ;

Rijo, Ivelise V. ;

Hedvat, Cyrus ;

Kobos, Rachel ;

Curran, Kevin ;

Steinherz, Peter ;

Jurcic, Joseph ;

Rosenblat, Todd ;

Maslak, Peter ;

Frattini, Mark ;

Sadelain, Michel .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (177)

[3] Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias [J].

Brentjens, Renier J. ;

Riviere, Isabelle ;

Park, Jae H. ;

Davila, Marco L. ;

Wang, Xiuyan ;

Stefanski, Jolanta ;

Taylor, Clare ;

Yeh, Raymond ;

Bartido, Shirley ;

Borquez-Ojeda, Oriana ;

Olszewska, Malgorzata ;

Bernal, Yvette ;

Pegram, Hollie ;

Przybylowski, Mark ;

Hollyman, Daniel ;

Usachenko, Yelena ;

Pirraglia, Domenick ;

Hosey, James ;

Santos, Elmer ;

Halton, Elizabeth ;

Maslak, Peter ;

Scheinberg, David ;

Jurcic, Joseph ;

Heaney, Mark ;

Heller, Glenn ;

Frattini, Mark ;

Sadelain, Michel .

BLOOD, 2011, 118 (18) :4817-4828

[4] Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 [J].

Brentjens, RJ ;

Latouche, JB ;

Santos, E ;

Marti, F ;

Gong, MC ;

Lyddane, C ;

King, PD ;

Larson, S ;

Weiss, M ;

Rivière, I ;

Sadelain, M .

NATURE MEDICINE, 2003, 9 (03) :279-286

[5]

Brown Jennifer R, 2014, Am Soc Clin Oncol Educ Book, pe317, DOI 10.14694/EdBook_AM.2014.34.e317

[6] Current status of adoptive immunotherapy of cancer [J].

Chang, AE ;

Shu, SY .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1996, 22 (03) :213-228

[7] T cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity [J].

Chmielewski, M ;

Hombach, A ;

Heuser, C ;

Adams, GP ;

Abken, H .

JOURNAL OF IMMUNOLOGY, 2004, 173 (12) :7647-7653

[8] CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma [J].

Chu, J. ;

Deng, Y. ;

Benson, D. M. ;

He, S. ;

Hughes, T. ;

Zhang, J. ;

Peng, Y. ;

Mao, H. ;

Yi, L. ;

Ghoshal, K. ;

He, X. ;

Devine, S. M. ;

Zhang, X. ;

Caligiuri, M. A. ;

Hofmeister, C. C. ;

Yu, J. .

LEUKEMIA, 2014, 28 (04) :917-927

[9] Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study [J].

Ciceri, Fabio ;

Bonini, Chiara ;

Stanghellini, Maria Teresa Lupo ;

Bondanza, Attilio ;

Traversari, Catia ;

Salomoni, Monica ;

Turchetto, Lucia ;

Colombi, Scialini ;

Bernardi, Massimo ;

Peccatori, Jacopo ;

Pescarollo, Alessandra ;

Servida, Paolo ;

Magnani, Zulma ;

Perna, Serena K. ;

Valtolina, Veronica ;

Crippa, Fulvio ;

Callegaro, Luciano ;

Spoldi, Elena ;

Crocchiolo, Roberto ;

Fleischhauer, Katharina ;

Ponzoni, Maurilio ;

Vago, Luca ;

Rossini, Silvano ;

Santoro, Armando ;

Todisco, Elisabetta ;

Apperley, Jane ;

Olavarria, Eduardo ;

Slavin, Shimon ;

Weissinger, Eva M. ;

Ganser, Arnold ;

Stadler, Michael ;

Yannaki, Evangelia ;

Fassas, Athanasios ;

Anagnostopoulos, Achilles ;

Bregni, Marco ;

Stampino, Corrado Gallo ;

Bruzzi, Paolo ;

Bordignon, Claudio .

LANCET ONCOLOGY, 2009, 10 (05) :489-500

[10] Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond [J].

Cohen, Cyrille J. ;

Li, Yong F. ;

El-Gamil, Mona ;

Robbins, Paul F. ;

Rosenberg, Steven A. ;

Morgan, Richard A. .

CANCER RESEARCH, 2007, 67 (08) :3898-3903

← 1 2 3 4 5 6 7 →